David Malcom Rodman - 17 Jul 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Reporting relationship: Chief Medical Officer
Issuer ticker: MLYS
Reported as of: 17 Jul 2026
Net transaction value: -$11,036
SEC form: 4
Accepted by SEC: 20 Jul 2026, 21:00:26 UTC
Prior SEC filing: 15 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Levy, Attorney-in-fact

Key filing fact

David Malcom Rodman filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 20 Jul 2026.

Key facts

This page summarizes David Malcom Rodman's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Jul 2026, 21:00.

Change

Previous filing in this sequence was filed on 15 Jul 2026.
Current net transaction value: -$11,036.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001672659 Primary reporting owner

Rodman David Malcom

Relationship: Chief Medical Officer
Address: 150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR
Signature: /s/ Adam Levy, Attorney-in-fact
Signature date: 20 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLYS transaction

Common Stock

Options Exercise

Transaction value
Shares: +416
Change %: +0.81%
Price: $15.44^*
Shares after: 51,800
Date: 17 Jul 2026
Ownership: Direct
Footnotes: F1

MLYS transaction

Common Stock

Sale

Transaction value: $11,036
Shares: -416
Change %: -0.8%
Price: $26.53
Shares after: 51,384
Date: 17 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLYS transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: -416
Change %: -11%
Price: $0.000000^*
Shares after: 3,334
Date: 17 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 416
Exercise price: $15.44
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

Footnote F2

The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.